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Background: Antibody mediated viral aggregation may impede viral transfer across mucosal surfaces by hindering
viral movement in mucus, preventing transcytosis, or reducing inter-cellular penetration of epithelia thereby limiting
access to susceptible mucosal CD4 T cells and dendritic cells. These functions may work together to provide effective
immune exclusion of virus from mucosal tissue; however little is known about the antibody characteristics required to
induce HIV aggregation. Such knowledge may be critical to the design of successful immunization strategies to
facilitate viral immune exclusion at the mucosal portals of entry.
Results: The potential of neutralizing and non-neutralizing IgG and IgA monoclonals (mAbs) to induce HIV-1 aggregation
was assessed by Dynamic light scattering (DLS). Although neutralizing and non-neutralizing IgG mAbs and polyclonal
HIV-Ig efficiently aggregated soluble Env trimers, they were not capable of forming viral aggregates. In contrast, dimeric
(but not monomeric) IgA mAbs induced stable viral aggregate populations that could be separated from uncomplexed
virions. Epitope specificity influenced both the degree of aggregation and formation of higher order complexes by dIgA.
IgA purified from serum of uninfected RV144 vaccine trial responders were able to efficiently opsonize viral particles in the
absence of significant aggregation, reflective of monomeric IgA.
Conclusions: These results collectively demonstrate that dIgA is capable of forming stable viral aggregates providing a
plausible basis for testing the effectiveness of aggregation as a potential protection mechanism at the mucosal portals of
viral entry.
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The induction of protective antibodies at mucosal portals
of virus entry may be essential for vaccine efficacy against
HIV-1 acquisition. Ideally, vaccination would induce
broadly neutralizing antibodies (bnAb) in the fluids present
at susceptible mucosal surfaces such as the lower female
genital tract and the rectum [1,2]. However this type of
antibody response has yet to be generated by current vac-
cine candidates and will likely require new immunogens
and vaccination strategies yet to be realized. Furthermore, it
remains unclear whether classical neutralization is a* Correspondence: r.shattock@imperial.ac.uk
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unless otherwise stated.prerequisite for mucosal protection or if other antibody
functions can reduce the risk of mucosal HIV-1 infection.
This critical question has been thrown in sharp relief
following the immune-correlates analysis of the human
RV-144 Thai efficacy trial that demonstrated a modest re-
duction in risk of HIV acquisition (31.2%) in the absence
of an efficient neutralizing antibody response. Here re-
duced acquisition of HIV infection correlated, not with
neutralizing activity, but with non-neutralizing binding
antibodies to variable regions 1 and 2 (V1V2) of the HIV-
1 envelope proteins (Env). Whether such responses are a
surrogate or mechanistic correlate of protection has yet to
be defined. Surprisingly, high systemic levels of specific
IgA, predominantly to the C1 region of Env, may have
mitigated the effects of protective antibodies most likelyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(ADCC). While systemic responses in the RV144 trial
have been studied in detail, the extent to which they re-
flect mucosal responses in terms of specificity, function or
isotype has not assessed and is the focus of on-going im-
munogenicity studies. Nevertheless these data highlight
the need to explore additional antibody functions that
may have protective efficacy at mucosal surfaces [3].
In addition to classical neutralization, mucosal antibodies
may impede viral transfer across mucosal surfaces by indu-
cing viral aggregation, hindering viral movement in mucus,
preventing transcytosis, or reducing inter-cellular penetra-
tion through the epithelia, thereby limiting access to sus-
ceptible mucosal CD4 T cells and dendritic cells. These
functions may work together to provide effective immune
exclusion of virus from mucosal tissue [4,5], and would
supplement Fc-receptor mediated phagocytic uptake and
degradation of opsonized virus, together with potential
ADCC mediated elimination of any initial foci of infection.
However, these functional activities are critically modulated
by immunoglobulin isoforms that differ in proportion and
in structure to those in blood, and by specificity, which
while showing considerable overlap to systemic antibody,
may also recognize distinct epitopes [6].
Typically IgA has been associated with immune exclusion
at mucosal surfaces. In the circulation, the two isoforms of
IgA (IgA1 and IgA2) are predominantly expressed in mono-
meric form. However at mucosal surfaces both isoforms
are expressed as dimer or polymers of monomeric IgA
linked by an integral joining chain (J chain) [7]. Binding of
the J chain to the polymeric Ig receptor (pIgR) triggers
active transport across mucosal epithelial cells and luminal
release following cleavage of pIgR, the mature secretory
IgA (scIgA) still complexed to the cleaved portion of pIgR
termed the secretory component (SC) [8]. In contrast, both
systemic and mucosal IgG isoforms (IgG1-4) are exclusively
monomeric. Mucosal transfer of IgG occurs by passive dif-
fusion and/or active transport mediated by the neonatal Fc
receptor (FcRn). The relative proportions of IgG and scIgA
isotypes differ by mucosal compartment where IgG pre-
dominates in vaginal fluids, while IgA dominates in rectal
secretions [9,10].
Although aggregation of HIV particles has been
proposed as a potential mechanism for decreased in-
cidence of initial infection [11-13], this has not been
tested experimentally. Furthermore the antibody char-
acteristics required for effective HIV aggregation have
not been defined, where the ability to form even
quasi-stable higher order complexes might be a rele-
vant factor in conferring protection by decreasing the
number of infectious units per inoculum. Indeed,
other mucosal viruses including poliovirus, rhinovirus,
and picornavirus are known to be susceptible to
neutralization by aggregation [14-17]. To the best of ourcurrent understanding, these types of complexes have
not been documented with HIV.
To determine the existence and feasibility of generating
viral aggregates by antibody cross-linking we have tested
the potential of neutralizing and non-neutralizing IgG and
IgA monoclonals from infected subjects as assessed by
Dynamic Light Scattering (DLS). This technique uses the
degree of Brownian motion in a liquid system to deter-
mine the size of particles and their heterogeneity by meas-
uring over time intervals the interference pattern of
photons deflected from a laser interacting with suspended
particles in solution, reviewed by Hassan et al. [18]. This is
known as a time-correlation function. Large particles have
a stable correlation over longer time frames. Small parti-
cles move more rapidly, resulting in an interference pat-
tern more dissimilar over a smaller time interval.
Env-specific antibodies of the IgG class were found to
be incapable of forming viral aggregates, although able
to cross-link recombinant trimeric Env protein. However
polymeric IgA monoclonals were able to efficiently ag-
gregate HIV-1 into discreet complexes. Furthermore, as-
sessment of post-vaccination IgA serum samples from
the RV144 Thai vaccine trial demonstrated significantly
larger particle formation than pre-vaccination IgA.
Knowledge of the antibody isotype and specificity
needed to induce aggregation may allow more specific-
ally tailored design of immunization strategies to facili-
tate immune exclusion at the mucosal portals of entry.
Results
HIV-1 Env specific IgG mAbs aggregate trimeric Env
protein but fail to induce viral aggregation
Initial experiments were performed to assess the ability of
HIV-1 Env specific monoclonal IgG antibodies to aggre-
gate recombinant HIV-1 Env protein providing a classical
two species system (antigen-antibody). A panel of Env-
specific monoclonal antibodies (mAbs) was assessed for
the ability to aggregate soluble trimeric gp140 (CN54
gp140) using dynamic light scattering (DLS) to determine
particle size. gp140 better represents the envelope spike of
HIV than monomeric gp120 and its trimeric structure dis-
plays three potential binding sites per molecule. This
protein was chosen because if its ready availability, stabil-
ity profile and our previous experience studying it’s bio-
chemical properties [19,20]. The rate of change in the
time-correlation function was used to calculate the het-
erogeneity within a sample, known as the polydispersity
index or PDI. A sample size ranges from 0 for a uniform
particle size to 1 for a random dispersion. This alone is
not a measure of aggregation, but gives insight into
changes in the composition of a sample, which tends to
correspond with formation of higher order complexes.
mAbs alone ranged in size from 4-12 nm, while soluble
gp140 measured 12.4 ± 2.4 nm, with a PDI of 0.17.
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Env were able to induce aggregation of trimeric protein
(Table 1, Column “gp140 Aggregation”). To test if this ef-
fect could be saturated, the stoichiometry was varied.
mAbs were added at a range of concentrations (0.5 - 50
μgml−1) to account for the fact that aggregate formation is
optimal at specific stoichiometry, related to antibody affin-
ity. The ratio of antibody to Env binding sites ranged from
a maximum of 11.5:1 to a minimum of 1:8.67. Aggregate
formation was observed with most antibodies. Optimal
aggregate formation was most common near a Ab:Env ra-
tio close to 1. Eighteen of the mAbs tested could form ag-
gregates at the maximal concentration of 50 μgml−1; at 0.5
μgml−1 aggregation was only seen with 3H12. All neutral-
izing antibodies (nAbs) targeting epitopes present on
CN54 gp140 formed aggregates. The multiple specificities
present in polyclonal HIV-Ig (pooled purified IgG from in-
fected individuals) allow for multiple cross-linking at a
wide range of concentrations and had a higher PDI. Here,
the potent ability to form aggregates likely reflects the
polyclonality of antibodies.
To correlate Env aggregation with neutralizing activity,
the potency of these antibodies was tested against HIV-
1BaL, a CCR5 tropic lab-adapted clade B strain of HIV-1,
in a TZM-bl assay. These cells express HIV1-1 receptors,
are highly susceptible to infection, and produce luciferase
in response to infection. Antibody concentrations were
used at the same levels as those capable of aggregating the
Env trimer. The majority of mAbs failed to inhibit infec-
tion (Table 1, Column “IC50”). The ability of mAbs to in-
duce complexes amongst Env trimers was not predictive
of the ability to block viral infection.
To test the ability of Env-specific antibodies to form
higher order complexes with whole virions, highly purified
HIV-1 was incubated with the same panel of mAbs. Purifi-
cation of viral particles by centrifugation has been shown
to retain functional Env in its native conformation
[21-23]. Purified viral particles alone had an average diam-
eter of 150.2 ± 2.1 nm, with a PDI of 0.15, indicating a
homogeneous population of particles. The liquid phase
measurement is larger than that traditionally defined by
electron microscopy (~120 nm) where sample processing
can condense the viral membrane [21,24].
Incubation of purified virions with the panel of Env spe-
cific IgGs had uniform results: the maximum change in
size of IgG treated virions was no more than twice the size
of an antibody (Table 1, Column “Virus Aggregation”),
with a modest increase in PDI. These results reflect the
ability of antibodies to bind and opsonize virions, but indi-
cate that each arm of an IgG molecule was not able to sta-
bly bind and bridge between different virions.
Lack of viral aggregation was not due to inability of anti-
body to bind whole virions. To confirm that IgG treated
virions were effectively opsonized and susceptible toaggregate formation, free anti-Env mAb was removed
using a 250 kD spin column, and a secondary anti-human
Fc antibody was added. This resulted in appreciable aggre-
gation with monoclonal (1F7), and polyclonal (HIV-Ig), as
well as antibody specific for host derived protein (HLA-
DR) (Additional file 1: Figure S1). These results indicate
that steric or flexibility limitations of IgG molecules re-
strict aggregate formation with virions.
In contrast to IgG, Env specific dimeric IgAs can induce
aggregation of HIV-1
The inability of all IgG class antibodies tested to aggregate
virions suggests they would be ineffective at mediating im-
mune exclusion by viral aggregation. Because the dIgA
structure affords increased valency, antibodies of this class
were next investigated. 2F5 was available as monomeric
and dimeric IgA1 and b12 as IgA2 mAbs. Also available
were an additional panel of 3 IgA1 isolated from patients’
serum from the CHAVI 001 cohort: ACL4, E10, and XA1
which contain mainly mIgA.
The well-characterized 2F5 mAbs binds to the MPER of
gp41 as well as interacting with the lipid component of the
viral membrane, while b12 binds to CD4 binding site in
gp120. To ensure that class switching of these antibodies
did not alter their affinity for their epitope, kinetic binding
measurements between purified virions and mAbs of the
IgG, IgA, and IgM class were made. The resulting affinities
varied between CCR5- (Additional file 2: Figure S2A) and
CXCR4-tropic (Additional file 2: Figure S2B) viral strains
although class switching antibodies altered the binding only
modestly. Affinities ranged from 10.8nM for b12 IgG bind-
ing HIV-1BaL to 104nM for 2F5 IgM binding HIV-1RF.
In sharp contrast to treatment with Env specific IgG,
DLS measurements on virions treated with 10 ugml−1
2F5 dIgA1 showed significant levels of viral aggregation
(Table 2). The average diameter of the preparation in-
creased from 150 nm to 225 nm and resulted in a four
fold increase in PDI from 0.15 to 0.63. These measure-
ments combined indicate the presence of higher order
complexes. 2F5 pIgM provided a less extensive increase
in particle size of 32.1 nm and a PDI of 0.41, indicating
that increasing mAb valency further was not sufficient
to induce more potent aggregation. Measurements made
with b12 dIgA2 antibody resulted in similar increases in
size with an increase diameter from 150 nm to 213 nm
and an increased PDI to 0.67. Screening the remaining
monomeric IgA antibodies failed to show significant ag-
gregate formation.
Separation of viral aggregates allows specific
characterization of their size and interpretation of the
number of virions per complex
DLS techniques on their own are restricted in that they
are not optimal for characterization of samples comprised
Table 1 Aggregation assessment of trimeric Env or HIV-1BaL virions incubated with antibody
Assessment of IgG antibodies for aggregation of gp140 and HIV-1
Antibody Epitope (residues) Trimeric CN54 gp140 Neutralization Purified HIV-1 BaL
gp140 Agg.1 Conc. range2 Ab Conc. Ab:Env ratio PDI3 IC50 Virus Agg.
1 Δ Virus size4 (nm) PDI3
HIV-Ig Polyclonal ++ 50-1 50 17:1 0.67 10.6 - 19.3 0.41
1B7 gp41 (ND) ++ 50-10 10 3.4:1 0.56 >50 - 5.4 0.23
5F3 gp41 cluster V ++ 50-2 5 1.7:1 0.53 >50 - 12.5 0.30
24G3 gp41 (526-543) ++ 50-5 5 1.7:1 0.49 >50 - 10.6 0.26
3H12 gp41 (ND5) ++ 50-.5 2 1:1.5 0.45 >50 - 4.0 0.33
b12 gp120 CD4bs ++ 50-2 5 1.7:1 0.54 0.75 - 12.7 0.34
G8 gp120 (dis) ++ 5-2 5 1.7:1 0.51 >50 - −6.4 0.21
1F7 gp120 V3 ++ 50-1 5 1.7:1 0.48 1.24 - 6.3 0.32
25C2 gp41 CD4i (526-543) + 50-5 10 3.4:1 0.35 >50 - −1.6 0.34
1H5 gp41 (579-613) + 50-2 2 1:1.5 0.32 >50 - 1.0 0.23
4B3 gp41 (579-613) + 50-5 5 1.7:1 0.31 >50 - −4.3 0.28
1B1 gp120 (CD4bs dis) + 50-10 10 3.4:1 0.37 >50 - 7.4 0.27
3D5 gp120 (ND) + 50-5 5 1.7:1 0.34 >50 - −12.4 0.21
2G6 gp120 (CD4bs dis) + 10-5 10 3.4:1 0.32 >50 - 1.4 0.26
3B7 gp120 (non-V3) + 50-5 10 3.4:1 0.28 >50 - 12.6 0.31
4D4 gp41 (579-613) ± 10 10 3.4:1 0.30 >50 - 16.2 0.28
1F11 gp41 (579-613) ± 10 10 3.4:1 0.27 >50 - 2.2 0.40
3D6 gp41 (604-617) ± 50-5 5 1.7:1 0.23 >50 - 9.8 0.27
2G12 gp120 (C2-C3-V4 glycan) ± 50-10 10 3.4:1 0.19 1.89 - 13.7 0.26
7B2 gp41 cluster I ± 50 50 17:1 0.27 9.65 - 11.0 0.38
2F5 gp41 MPER (662-667) - N/A N/A N/A 0.21 2.73 - 14.6 0.37
4E10 gp41 MPER (824-830) - N/A N/A N/A 0.20 >50 - −1.5 0.22
The average size of the preparations was measured by dynamic light scattering. Data is the average of three experiments, each measured in triplicate. For CN54gp140, Ab concentration, Ab:Env ratio and PDI are
reported for optimal aggregate formation conditions. For HIV-1 BaL, Δ Virus size and PDI are reported for 10 μgml−1. All concentrations are in μgml−1.
1Aggregate formation was scored by the maximum size measured: ++ for particles > 100 nm; + for 40 ≤ 100 nm; ± for 20 < 40 nm, – for ≤ 20 nm.
2Concentration range where the gp140-Ab complexes scored positive for aggregation.
3Relative heterogeneity of preparations is evaluated by polydispersity index (PDI).















Table 2 Env-specific antibodies of the IgA class were
incubated purified HIV-1 and particle size determined by
dynamic light scattering
Assessment of aggregation of HIV-1BaL by IgA-class mAbs specific
for Env
Antibody Isotype Virus Aggregation1 Δ Viral Size (nm) PDI
2F5 IgG - 14.6 0.19
dIgA ++ 75 0.63
pIgM + 32.1 0.41
b12 IgG - 12.7 0.27
dIgA ++ 63 0.67
ACL4 mIgA + 26.9 0.29
E10 mIgA - 17.3 0.36
XA1 mIgA - −4.1 0.21
The change in the size of viral particles from virus alone (150.2 nm), and the
polydispersity index (PDI) of virus-Ab preparations assesses the presence
of aggregates.
1Aggregate formation was scored by the maximum size measured: ++ for Δ >
50 nm; + for 25 ≤ 50 nm; – for ≤ 25 nm.
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to better characterize the degree and heterogeneity of viral
aggregates induced by Env specific dIgA, separation of the
sub-populations present in each preparation was neces-
sary. This was achieved by size-exclusion chromatography
(SEC) system followed by in-line DLS measurements. SEC
can separate antibody from uncomplexed virions and dif-
ferent degrees of aggregation, enabling increased precision
in sizing measurements.
Purified virions incubated with 2F5 IgG were seen to
elute as a single species, and measure 176 ± 6 nm, with a
PDI of 0.16 (Additional file 3: Figure S3). Three in-line
detectors were employed; the infrared (IR), ultraviolet
(UV), and DLS detector agreed with the elution timing
of 23.4-23.6 minutes and the absence of any other parti-
cles at a detectable concentration outside of the void
volume.
In contrast, SEC-DLS of virions incubated with 2 F5
dIgA1 revealed three discrete populations outside of the
void volume. These measured 180 ± 12 nm (PDI 0.17),
298 ± 18 nm (PDI 0.19), and 450 ± 21 nm (PDI 0.22) in
diameter and eluted at 23, 21, and 19 minutes respect-
ively (Figure 1). There was a return to baseline for each
of the detectors between the particles being eluted, indi-
cating formation of discrete complexes rather then a
continuous distribution of particle sizes. Random bridg-
ing of particles would not result in separate populations
being generated, but a continuous distribution. This ob-
served ordered aggregation into discrete size fractions
could provide a stoichiometric basis for understanding
the mechanisms of aggregate formation.
Aggregates were then modeled using a stacked
spheres methodology. Here, virions are modeled as non-
overlapping spheres which fit into a volume afteradjusting for the density of either close packing (ρ =
0.74) or random packing (ρ = 0.63) of virions. The num-
ber of virions in a complex (Nv) is estimated by the vol-
ume of an aggregate (Vagg) multiplied by the packing
density (ρ) divided by the volume of a single virion Nv =
Vagg × ρ × Vvir
− 1. This resulted in different structures
being identified. The smallest complex being composed
of antibody opsonized virions or 2 viral particles bound,
without external antibody. The 298 nm complex is rep-
resentative of 6 to 8 virions held in complex. The largest
peak, with a 450 nm diameter, is indicative of between
24 and 30 virions in large complexes. The shape of com-
plexes cannot be measured using DLS, and calculations
are based on the observation that the complexes do not
randomly associate, but instead form populations. The
detectors returning to baseline signal between each spe-
cies justified this reasoning.
The relative concentration of each species can also be
estimated, based on the signal intensity corrected for the
relationship between signal intensity and particle size.
Larger complexes scatter a disproportionate amount of
light relative to an equal number of smaller particles.
Virion-2F5 dIgA preparations indicated that approxi-
mately 85% of signal was attributable to the 176 nm
peak, 10% within the 298 nm peak and 5% from the lar-
gest aggregates. Normalizing for the number of virions
contained within each group, 2F5 aggregation is approxi-
mately 50% efficient with 50% of virions in the 176 nm
fraction, 40% in the 298 nm and 10% in the 450 nm
peak.
Assessment of virions incubated with b12 IgG using
the SEC-DLS system was similar to that with 2F5 IgG
(Additional file 4: Figure S4). Virions incubated with b12
dIgA2 separated into two discrete populations (Figure 2),
one with a mean diameter of 180 ± 21 nm, PDI 0.24, and
one at 310 ± 16 nm, PDI 0.21. For b12 dIgA2, unlike 2F5
dIgA1, there was only one higher order population
formed. Employing the same stacking spheres model in-
dicates that virus with b12 dIgA forms single opsonized
virions and aggregates of 6-8 virions. Correcting the for
the number of individual virions contained within each
fraction, b12 dIgA preparations indicated that 87-92% of
total signal came from the 180 nm peak, thus 35-40% of
the viral particles were aggregated.
Serum samples from the RV144 vaccine trial show a
modest ability to aggregate vaccine-matched virions
The RV144 Thai vaccine trial represents the first clinical
study to demonstrate any impact on HIV-1 acquisition
providing a modest protective efficacy [25]. In this trial
study volunteers were vaccinated in a prime/boost regime
using recombinant canary poxvirus (ALVAC-HIV) and
two gp120 proteins (AIDSVAX B and E) [26]. Early ana-
lysis suggested the observed protective efficacy did not
Figure 1 Size-exclusion chromatography (SEC) and dynamic light scattering in tandem enable more accurate characterization of the
complexes formed with 2F5 IgA. Virus incubated with 2F5 dIgA was separated over a size exclusion column and followed by particle detection
by (A) infrared, (B) ultraviolet, and (C) DLS detection. Size was determined for each peak eluted from the SEC system and the % of signal
intensity corresponding to complex size is shown. Three peaks were detected with dIgA preparations, eluted at (D) 19, (E) 21, and (F) 23 minutes,
measuring 450 nm, 298 nm and 180 nm, respectively. Experiments were performed in triplicate. Results shown are from one
representative experiment.
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munity, and was likely affected by non-neutralizing anti-
body function [27,28]. Antibody responses were capable
of binding infectious virions [29]. One of a number of hy-
potheses currently being evaluated is that virus might have
been complexed with Env-specific dIgA at mucosal sur-
faces leading to immune exclusion. Nevertheless, high
levels of HIV specific serum IgA antibodies correlated
with reduced vaccine efficacy. In the systemic compart-
ment, coating of virus with IgA may be detrimental if
competing for binding with IgGs of similar specificity
blocks Fcγ-Receptor mediated antiviral activity [28].Although mucosal samples were not collected as a part of
the initial RV-144 study, serum samples were collected
over the course of the vaccination regime. In the absence
of mucosal samples we applied our aggregation assay to
the analysis of serum IgA. Levels of serum IgA are variable
from one individual to another, and the amount of dimeric
IgA present in human serum can range substantially, from
2 to 30% of total Ig [30], therefore serum samples were
initially screened to select those with high levels of IgA
binding to the autologous vaccinating Clade A/E rgp120
protein, strain A244. All of the patients in this study
remained uninfected throughout the course of the vaccine
Figure 2 Size-exclusion chromatography and dynamic light scattering in tandem allow more accurate characterization of viral
complexes formed with b12 IgA. Virus incubated with b12 dIgA was separated over a size exclusion column and followed by particle detection
by (A) infrared, (B) ultraviolet, and (C) DLS detection. Size was determined for each peak eluted from the SEC system and the % of signal
intensity corresponding to complex size is shown. Two peaks were detected with dIgA preparations, eluted at (D) 21.5 and (E) 23 minutes,
measuring 310 nm and 180 nm, respectively. Experiments were performed in triplicate. Results shown are from one representative experiment.
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of our knowledge. IgA was then affinity purified from the
serum taken before the first (visit 1 (v1)) and after the final
vaccination (visit 8 (v8)) of 29 volunteers as previously de-
scribed [27,28].
To determine whether the samples contained monomeric
or dimeric IgA, native western blotting with anti-human
IgA-FC was performed. Both monomeric and dimeric
forms of IgA were present in the pre-immunization and
post-immunization samples (Additional file 5: Figure S5).
IgA samples were then assessed for HIV-1 aggregation at a
range of concentrations (1, 2.5 and 10 μgml−1). The viralstrain used (A244) was matched to the clade E gp120 pro-
tein used for vaccination. Purified HIV-1A244 virus grown
in pooled PBMCs had an average diameter of 216.5 ±
3.2 nm, and a PDI of 0.29, which was larger and more het-
erogeneous than that seen with the BaL virions used in pre-
vious experiments, but this was repeatable between viral
preparations (Additional file 6: Figure S6A). To control for
any clustering within the purified IgA preparations, total
IgA was screened in the absence of any virions. These re-
sults indicated a homogenous particle size for the IgA with
measurements ranging from 6 to 12 nm (Additional file 6:
Figure S6B).
Stieh et al. Retrovirology 2014, 11:78 Page 8 of 16
http://www.retrovirology.com/content/11/1/78When pre-immunization samples (Visit 1) were incu-
bated with HIV-1A244 at 10 μgml
−1 there was no clear
evidence of aggregate formation observed in any sample
with a decrease in the average diameter relative to un-
treated virions seen in some patients. The observed de-
crease is caused by high levels of free antibody in
solution with a diameter that is an order of magnitude
smaller than virions, decreasing the mean particle size.
The average size of visit 1 samples was 218.3 ± 13 nm.
As visit 1 samples represent pre-immunization sera, the
antibody in these preparations will not be specific for
HIV-1, but will include all IgA antibodies constitutively
expressed by the individual donor.Figure 3 Sizing measurements of pre-immunization compared to post-
paired size measurements for pre and post immunization IgA samples incuba
hour and measured using dynamic light scattering. Each circle shown represe
times for each sample. Horizontal dashed line indicates the size of untreated
measurements for each patient at each visit.Final visit samples were then analyzed in the same man-
ner. Particle size was larger with post-immunization IgA at
10 μgml−1 for most patients (Figure 3A). The average diam-
eter of post-immunization samples was increased to 235.9 ±
20.5 nm. Lower antibody concentrations had no effect. The
differences observed revealed a highly significant increase in
the size measurements made between visit 1 and visit 8
samples (p < 0.0001) (Figure 3B) using Wilcoxon’s matched
pairs test to measure significance. This indicates that there
was an effect, specific to the vaccination status of this panel
of individuals. When compared by repeated measures ad-
justed 1-way ANOVA (Bonferonni adjusted), 10 of 29
donors’ visit 8 IgAs resulted in sizes with a statisticallyimmunization samples for RV144 serum IgA. (A) Scatter plots and (B)
ted with HIV-1A244. Purified virions and IgA samples were incubated for 1
nts the average of 3 measurements, with experiments performed three
viral preparations. Error bars indicate the standard deviation within the
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< 0.05). One patient in particular, 728339, had a highly statis-
tically significant (p < 0.01) increase diameter from 191 to
248 nm.
To compare changes in size with functional activity we
applied an infectious capture assay to determine the ability
of purified IgA to bind infectious virions. 22 (subtype A/E
CM244 or transmitted/founder subtype B WITO) and 29
(lab adapted subtype B NL4-3) vaccinees with detection of
HIV-1 Env binding antibody responses were selected for
analysis (Figure 4). Pre-immunization samples demon-
strated a background of infectious viral capture ranging
from 0% to 11.1%. After immunization the percentage of
tested vaccinees with infectious virion capture capacity
were 31.48% (10/29) for NL4-3 and 60.86% (14/23) for
vaccine strain CM244, respectively. The transmitted/
founder strain WITO was captured by 31.82% (7/22) vac-
cinees. Pair-wise comparison (Wilcoxon matched-pair
test) between pre and post-immunization IgA shows the
fraction of vaccine strain subtype CM244 infectious virus
capture by the antibody bound fraction increased signifi-
cantly after immunization (p = 0.0003). The immune re-
sponse seen amongst these participants was consistent in
their ability to specifically capture infectious virus of au-
tologous vaccinating strains of HIV-1CM244 [31]. However
capture of infectious virions was distinct to binding to
consensus soluble gp140 or gp120 from the vaccinating
strain CM244 [29].Figure 4 RV144 Vaccine Induced IgA mediated Infectious HIV-1
Virion Capture. Purified plasma IgA at visit 1 (pre-vaccination) and
visit 8 (2 weeks post last vaccination) from 22 (CM244 or WITO) and 29
(NL4-3) vaccinees with detectable HIV-1 Env binding antibody
responses were selected and measured in infectious HIV-1 capture
assays using micro-plate based assay [29]. Relative light units (RLU)
produced by infected target cells quantify the amount of infectious
virus bound. Dashed line (RLU ≥1000) indicates positive samples. The
percentage of tested vaccinees with virion capture capacity are 34.5%
(10/29) NL4-3, and 60.9% (14/23) for lab adapted strain NL4-3 and
CM244, respectively. The transmitted/founder WITO was captured by
31.8% (7/22) vaccinees. Dashed line indicates positivity threshold,
defined by the background levels of capture (≥1000).A total of 22 functional antibody assays were per-
formed on post-vaccine serum IgG and IgA purified
from the same RV144 donor pool [32]. To understand
what antibody effector functions or specificities were as-
sociated with post-vaccination IgA aggregation results, a
multiple regression analysis was performed against the
DLS assay results (Table 3). 3 statistically significant (p <
0.05) negative correlates were identified: ConSgp140
Binding antibody multiplex assay (BAMA), capture of
viral strain NL4-3 by IgA, and the A244gp120gD-
BAMA assay. Pooling the antigen binding results into a
“family” outcome provides a highly statistically signifi-
cant negative correlate as well. There were no statisti-
cally significant positive correlations identified; the
strongest predictive value was between binding of IgG to
the C5 domain of gp120 (p = 0.056), although there was
only enough material to perform this assay on 11 do-
nors. No other epitope mapping, ADCC or virus
neutralization results were predictive of the DLS assay.
The virus capture of HIV-1CM244 IgA also failed to pre-
dict the DLS results, which was unexpected. The lack of
association between well defined antibody functionalities
and potential for aggregation indicates that the DLS
assay is evaluating a unique niche in immunological
activity.
To summarize the results of the RV144 samples,
serum IgA incubated with purified HIV-1A244 virions re-
sulted in a statistically significant increase in particle size
in 31.82% of vaccinees. Increased ability to affect virion
size was paralleled by an increase in capture of infectious
virions after vaccination however there was not direct
correlation between the two. The moderate effect of ag-
gregation using these samples is likely due to the low
concentration of dimeric relative to monomeric IgA in
the serum.
Discussion
We have assessed for the first time antibody characteris-
tics determining the potential to form aggregate com-
plexes with HIV-1. Initial experiments with soluble
trimeric Env and IgG mAbs demonstrate how the stoi-
chiometry of aggregation is an important consideration:
excess antigen or antibody reduces the potential for
complexes to form, typical of a prozone effect. Most Env
specific IgGs were able to form Env-aggregates to some
degree, but efficiency and optimal concentration varied
significantly. These data indicate that aggregate forma-
tion is likely determined by multiple binding modes. The
same IgG mAbs were unable to aggregate virions. Thus
while Env specific IgGs possess the intrinsic capacity to
bridge between trimers, they are unable to stably bind
trimers on opposing viral membranes.
The inability of IgG to aggregate HIV-1 most likely re-
flects steric restriction based on presentation of the trimer
Table 3 Correlation between antibody function and DLS results in post-vaccination serum
Summary of correlations between outcomes of antibody function assays and aggregation
Immunoglobulin activity assay Correlation to v8 Size (nm) n: Donors with
correlated dataViral strain/Epitope Assay type Isotype Pearson R Adj. P value
ConS gp140 Antigen binding IgA −0.538 0.014 20
NL4-3 Virus capture IgG −0.486 0.022 22
A244 gp120 gD- Antigen binding IgA −0.461 0.041 20
gp120 C5 domain Epitope mapping IgG 0.591 0.056 11
A244 Virus capture IgG −0.441 0.067 18
TH023 Neutralization Mixed −0.261 0.171 29
MN gp120 Antigen binding IgA −0.308 0.186 20
gp120 C1 domain Epitope mapping IgG 0.373 0.259 11
MN Virus capture IgG −0.205 0.372 21
MN Virus capture IgA 0.169 0.398 27
A244 gp120 gD+ Antigen binding IgA −0.153 0.519 20
MN Neutralization Mixed −0.116 0.548 29
gp120 V3 domain Epitope mapping IgG 0.182 0.593 11
A244 gD+ ADCC IgG 0.080 0.684 28
gp120 V2 domain Epitope mapping IgG 0.127 0.709 11
WITO Virus capture IgG 0.086 0.735 18
WITO Virus capture IgA −0.077 0.742 21
NL4-3 Virus capture IgA −0.059 0.772 27
CM243 ADCC IgG −0.027 0.891 29
Multiple strains Binding breadth IgA −0.022 0.911 29
Results for ADCC, neutralization and IgG Virion capture have been previously reported [27,29,32].
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proach angles. The inability to aggregate virions is not re-
lated to monoclonality as polyclonal HIV-Ig was also
unable to aggregate HIV. Aggregation requires monova-
lent antibody binding with an orientation where one of
the two Fab arms is directed towards the solution and
available for bridging. This is compounded by the low
density of Env spikes on individual virions (7-15) and the
distance between membrane-anchored Env complexes on
opposing virions. An alternative scenario would be that of
bivalent binding of individual HIV mAbs, either to the
same trimer or between trimers on the same virion pre-
cluding availability of free Fab arms for aggregation, how-
ever affinity studies suggest this is not the case [33].
Indeed heteroligation of Env spikes has only been reported
for chimeric bispecific antibodies [34]. Furthermore, the
observation that aggregation could be induced by second-
ary addition of anti-IgG antibody suggests that neither
spike density nor the distance between Env complexes on
opposing virions is limiting (the binding of the primary
Env mAb being directly proportional to spike density).
These data demonstrate effective opsonisation of virus by
IgG and add support to the hypothesis that the Fab ap-
proach angle is likely the dominant factor in determiningvirion aggregation. These data are in line with earlier stud-
ies implying the angle of approach between epitope and
Ab is the principle determinant for the potential to aggre-
gate poliovirus [35]. The shape of IgG likely restricts posi-
tioning of Fabs on the Env trimer, causing the second free
Fab arm to be unavailable for interaction with a second
trimer. In contrast to IgG, IgA1 has a longer hinge region
that may have reduced steric restrictions, however class
switched monomeric versions of 2F5 IgA1 was also unable
to aggregate HIV despite having similar ability to bind
whole virions as their IgG counterparts.
In contrast to monomeric immunoglobulins, both di-
meric 2F5 IgA1 and b12 IgA2 were capable of inducing
aggregation. Here, two monomers are connected end-
to-end through their Fc regions by a flexible joining
chain (J chain). As a result the Fabs of each monomer
are diametrically opposed, with access to a broader array
of orientations. Thus the Fabs of each monomer are able
to have favorable and independent approach angles to
trimers on different virions [36]. However the propor-
tion of virions aggregated and the size of higher order
complexes were influenced by antibody specificity.
2F5 dIgA1 was able to aggregate up to 50% of virions
into aggregates of 6-8 or 24-30 virions. This suggests the
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peared insufficient to cause pan-virion aggregation [37].
The observation of two discrete orders of aggregation,
rather than a dispersed size distribution, suggests these
two populations may reflect differences in epitope ex-
posure on discrete virion populations. The principal epi-
tope of 2F5 mAb is within the MPER of gp41. This is
thought to be occluded on functional trimers of primary
virus and on HIV-1 BaL used here [38], but is transiently
exposed on receptor/coreceptor binding [39]. However,
the 2F5 epitope would be accessible on non-functional
Env forms such as non-cleaved gp160 and those gp41
molecules undergoing spontaneous triggering, having
shed their gp120. Whether the two aggregate popula-
tions represent different presentations of gp41 or levels
of MPER exposure requires further investigation. An
alternative explanation would be the difference in the
distribution of Env spikes on immature and mature par-
ticles, being randomly distributed on the former, while
tending to cluster into a single small domain with de-
creased inter-spike distances on the latter [40]. This is
less likely given that this would similarly influence b12
dIgA2. Indeed b12 dIgA2 produced a single aggregate
peak of 6-8 virions that comprised 35-40% of total vi-
rions. It is unclear at this stage whether the differences
in formation of higher order aggregates between 2F5
IgA1 and b12 IgA2 reflect difference in antigen specifi-
city or differences in hinge length and rigidity between
IgA1 and IgA2. These preliminary data suggest that ag-
gregation is dependent upon the distribution of epitope
exposure across a virion population. Study of a wider
panel of dIgA of varied specificity with matched IgA1/2
isotypes is now needed to understand the impact on for-
mation of aggregate complexes.
Analysis of serum IgA samples from RV144 vaccinated
subjects with high systemic IgA binding antibody dem-
onstrated a small but highly statistically significant in-
crease in complex size. Of the 22 measurements tested
for correlation with aggregation, 3 measurements involv-
ing binding and virion capture were negatively correlated
with virion aggregation (p < 0.05, adjusted for multiple
comparisons; R values of -0.461 to -0.538). This weak
correlation supports the finding that virion aggregation
is a distinct immune measurement from binding and vir-
ion capture. The RV144 + gD gp120 immunogen con-
taining an N terminal 11 amino acid deletion was
associated with enhanced antigenicity for C1, V2, and
V1/V2 conformational epitopes [41]. Thus, the observed
negative correlation with binding to gD- A244 and ConS
gp140 might be a surrogate for lower levels of IgA anti-
bodies with the epitope specificity required for efficient
aggregation. The negative correlation with IgG viral cap-
ture of NL4-3 is less clear. Interestingly, high levels of
serum binding IgA specific for variable regions 1 and 2(V1V2) of gp120 were correlated with reduced vaccine
efficacy [42]. One proposed explanation is that mono-
meric Env-specific IgA blocked the binding of C1 spe-
cific ADCC mediating IgG [28]. We find no correlation
between the DLS results and C1 binding. Our observa-
tion that specific IgA effectively opsonized A244 virions
suggests an alternative but not mutually exclusive mech-
anism: IgA may diminish specific IgG binding and as a
consequence reduce FcγR mediated phagocytosis and/or
complement fixation. This raises critical questions as to
the influence of IgA responses for HIV vaccine efficacy
in general. While vaccinations in the RV144 trial also in-
cluded HIV-1 strain MN, there was insufficient purified
serum IgA available to assess it potential aggregation.
The majority of the IgA in the serum is monomeric
and, based on data from these studies, would opsonize
but not aggregate virions. Monomeric IgA is unable to
trigger complement or engage FcγR antiviral activity,
thus competition with IgG for binding might be detri-
mental. However the concentration of serum IgG is on
average 4-fold higher than IgA. For specific monomeric
IgA to have a significant impact it would require an af-
finity sufficient to outcompete the higher concentration
of IgG. It would also be premature to exclude an anti-
viral role of the FcαR on IgA opsonized virions.
At mucosal surfaces IgA is expressed in its dimeric
form with potential to induce virion aggregation and en-
abling immune exclusion. In this study we have exam-
ined the potential of two neutralizing antibodies to
aggregate HIV-1. These initial studies indicate different
forms of aggregation based on epitope specificity and
isotype (IgA1/IgA2). Viral aggregation may augment the
protective efficacy of neutralizing antibodies. This is sup-
ported by a recent study in rhesus macaques demon-
strating that the dIgA1 isoform of the neutralizing MAb
HGN194 afforded the best in vivo protection (relative to
IgG1 and dIgA2) against rectal challenge [43]. The ex-
tent to which non-neutralizing antibodies might mediate
similar protective effects is likely dependent upon their
epitope expression on infectious virions.
Conclusions
In summary, to the best of our knowledge, this study dem-
onstrates for the first time the capacity of Env-specific
antibodies to cross-link HIV-1 virions into aggregates.
The ability to form aggregated immune complexes was
determined by the valency of the antibody, effectively in-
duced by polymeric but not monomeric isoforms. Both
the degree and higher order structure of aggregate forma-
tion was seen to vary based the epitope specificity of the
dIgA. Indeed, the two neutralizing dIgAs aggregated a
subset of virus reflective of the population of virions con-
taining forms of Env exposing their specific epitope. Fur-
ther studies are now needed to determine the impact of
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to determine whether this function is synonymous or inde-
pendent of neutralization. Furthermore, mucosal sampling
within clinical trials, and specifically follow on studies from
the RV144 protocol, will be important to understand the




Antibodies were obtained from Polymun Scientific (Vienna,
Austria) unless otherwise specified. 2F5 IgG, IgA, and IgM
were purchased from Polymun (Vienna, Austria) and
shared through the CHAVI consortium. Antibodies b12
IgG, monomeric b12 IgA (mIgA) and dimeric IgA (dIgA)
were donated by Dennis Burton. CN54 gp140 was chosen
for analysis based on availability of clinical grade material
and was also obtained from Polymun Scientific. The follow-
ing reagents were obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH: HIV-1 strains BaL and RF are donated by Dr.
Suzanne Gartner, Dr. Mikulas Popovic and Dr. Robert
Gallo; T cell line PM1 was donated by Dr. Marvin Reitz;
HIV-Immunoglobulin (HIV-Ig) was obtained from NABI
and National Heart Lung and Blood Institute from Dr. Luiz
Barbosa. Serum IgA samples were isolated from RV144
study participant samples and shared through the CHAVI
consortium. Human isotype controls were purchased from
Sigma-Aldrich.
Viral culture and purification
Chronically infected PM-1 cells were established follow-
ing infection with HIV-1BaL or HIV-1RF as previously de-
scribed [44]. Strain HIV-1A244 was grown in PBMCs
pooled from 10 donors and collected at peak viral anti-
gen production. Viral production was quantified by viral
capsid (p24 antigen) release, as measured by ELISA
(NCI Frederick, MD) according to the manufacturer’s
protocol. Supernatants were harvested to produce a viral
stock when p24 levels were greater than 250 ngml−1. Vi-
rions were inactivated by incubation with aldrithol-2
(AT-2) for 1 h at 37°C [45].
To purify virions and microvesicles from other lipid
vesicles, a protocol similar to those previously described
was used [24]. Briefly, cell supernatant stocks were lay-
ered on top of a 17-25% sucrose solution and spun at
100,000 g in a SW55Ti rotor until pelleted. Supernatants
were aspirated, and pellets were resuspended in PBS
supplemented with 1% bovine serum albumin (BSA) and
5 mM EDTA (Sigma-Aldrich). CD45 conjugated mag-
netic beads (Miltenyi Biotec) were added at 10 μlml−1
relative to initial stock. This preparation of lipidic vesi-
cles was incubated at 4°C with gentile mixing for a 4 to
6 hours before depletion according to the manufacturer’sinstructions. Immune depleted virions were pelleted at
150,000 x g on 25% sucrose cushions for 60 minutes and
resuspended in PBS for analysis. Purified HIV-1BaL and
HIV-1RF preparations had a Z-average diameter of
150.2nM with a polydispersity index of 0.150, in agree-
ment with previous descriptions of viral preparations
[21,24].
Binding kinetics
Determinations of the affinity and relative avidity of
HIV-1 virions for monoclonal antibodies 2F5 and b12
were assessed on a RapID4 acoustic biosensor (TTP
Labtech). Antibody of interest and an inert control of
each isotype were bound on the flow cell surface using a
carbodiimide (EDC) and N-hydroxysuccinimide (NHS)
linkage. All procedures were performed at a flow rate of
25μlmin−1. Antibody to be coupled was diluted to a con-
centration of 50 μgml−1 in 100 mM sodium acetate at
pH 4.5. Capping was performed with 0.5 M ethanol-
amine, pH 8.0. Sensor cassettes were then conditioned
with 100 mM glycine, pH 2.5 with 0.025% Tween 20.
Virions were allowed to flow over the Ab coated sur-
face at a range of concentrations from 10 ngml−1 to 1.0
μgml−1 p24 in PBS and for 3 minutes, followed by dis-
sociation. Surfaces were regenerated by washing with
100 mM glycine buffer at a pH of 2.5 with 0.1% Tween
20. Experiments were performed in triplicate. Affinities
for all virus-antibody binding systems were calculated
according to the Langmuir kinetic model.
Dynamic light scattering size measurements
Assay development
Viral aggregation has not previously been studied for
HIV-1 or to our knowledge, any other enveloped viruses
aside from analysis by electron microscopy. To make
measurements of aggregate formation for many anti-
bodies at a range of concentrations required developing
a novel methodology. Size determination was carried out
using a Malvern ZetaSizer ZS Nano (Malvern Instru-
ments, England), using ZetaSizer software v7.01 in dual
angle (173° backscatter and 7° forward scatter) light scat-
tering mode. Samples were maintained at 37°C before
and during measurements. Preparations were considered
to be composed primarily of protein, so that the refract-
ive indexes of samples could be held constant. The light
scattering technique uses a time-correlation function to
determine the size of suspended particles diffusing due
to Brownian motion. Samples that self correlate for lon-
ger time scales are larger than ones where the time-
correlation function decreases rapidly.
The slope of the time-correlation function determines
the polydispersity of a sample. Materials that are homo-
geneous will have a more steeply sloped time-correlation
function (and lower polydispersity index, (PDI)) than
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fectly homogeneous sample, to 1 for a random distribu-
tion of sizes. Differences in the PDI can be used to
assess changes in heterogeneity between similarly pre-
pared samples. The value of the PDI is not indicative of
any absolute property, but measures the degree of
“sameness” within a sample.
Assay development proceeded from initial measurements
that were based on the concentration of virions used to de-
termine that a single population of particles was present in
the purified viral preparations. Purified virions were used at
a concentration of 25 μgml−1 p24 protein. Aggregate for-
mation was stable from 1 hour up to 6 hours at 37°C, al-
though lower temperatures did not abrogate aggregate
formation with all antibodies tested. Extended time frames
resulted in variability in readings, attributable to decreased
viral integrity over time.
While virions were incubated a range of antibody concen-
trations, results reported are exclusively from 10 μgml−1, as
this was most favorable for complex formation. When a
secondary anti-human or anti-murine IgG antibody (Sigma-
Aldrich, St. Louis, USA) was used, after incubation of virus-
antibody preparations, free antibody was removed by
passing the sample through a 250kD spin column (Promega,
Madison, USA). Secondary antibody was added at a concen-
tration of 5 μgml−1 and samples were incubated for
30 minutes at 37°C. Sizing measurements were made in the
same manner as for virus-antibody preparations.
SEC-DLS determination of viral aggregation
DLS measurements alone are very precise for measure-
ment of the size of a monodisperse suspension. When
multiple species are present, such as in the case of viral
aggregates in the presence of non-aggregated virions,
DLS accuracy decreases. Separation of the components
of a complex mixture by size exclusion chromatography
(SEC), followed by DLS measurements of each fraction
allows accurate characterization of each species present.
Antibody and purified virus complexes were prepared
according to the same antibody-virus ratios as for bulk
DLS measurements. Separation was done on a TOSOH
G4000SW SEC using a Gilson HPLC system with model
305 pumps with a manual injection loop. A mobile
phase of PBS with 0.05 mM EDTA was used at a flow
rate of 500 μlmin−1. DLS measurements were acquired
continuously and stored every 3 seconds with ZetaSizer
software v7.01.
Binding antibody assessment
Binding antibody multiplex assays for IgG and IgA and
purification of plasma IgA were performed as previously
described [28,46]. Plasma IgA was purified by peptide M
purification as previously described [28]. Confirmatory
IgA and IgG binding assays demonstrated Env specificIgA binding and depletion of IgG below detectable
levels.
Microplate infectious virion capture assay
Infectious virion capture assay was performed as previ-
ously described [29]. Briefly, Microplates (NUNC) were
coated overnight at 4°C with Goat Anti-Human Serum
IgA (Jackson ImmunoResearch Laboratories) at a concen-
tration of 2 μgml−1 diluted in PBS. After coating and
washing, coated plates were blocked for 2 hr with PBS
supplemented with 5% Goat serum, 5% milk, 0.05%
Tween. The indicated concentration of antibodies was
mixed with the viral stock containing 1.5 x 107 viral RNA
(measured by RT-PCR) and then centrifuged 90 min at
2,000 rpm. Then the mixture was centrifuged at 21,000 x
g for 1 hour at 4°C to remove the virus-free antibody, the
pellet was resuspended in the same volume of PBS. 50 μl
of the immune complex mixture was added to each coated
well in triplicate wells for 90 min. The wells were washed
4 times and the susceptible target cells (M7-Luc indicator
cells or A3R5 cells (for virus T/F WITO)) in 100 μl were
added. HIV-1 infection was assessed on day 7 after infec-
tion for M7-Luc and on day 6 for A3R5 cells by luciferase
assays. For M7-Luc firefly luciferase assay, 100 μl super-
natant was removed, and 100 μl Britelite (Perkin Elmer)
was added to each well. After 2-min incubation, the
150 μl lysate was used to measure HIV-1 infection as
expressed as relative luciferase units (RLUs). For A3R5
Renilla luciferase assay, luciferase expression of infected
cells was measured with the Renilla luciferase assay kit
(Promega) and read on a Berthold E & G luminometer
using MicroWin software.
Statistical analysis
The statistical significance of results was determined by
nonparametric analysis employing Wilcoxon’s matched
pairs, Pearson’s correlation, or 1-way ANOVA with the
appropriate subtest as specified using GraphPad Prism
5.0 software (Graphpad Software Inc., La Jolla, CA).
Multiple Pearson regression analysis of antibody func-
tions was performed in R using and the statistical signifi-
cance of the correlations was adjusted by the Bonferonni
correction.
Additional files
Additional file 1: Figure S1. Addition of a secondary anti-Fc antibody
to IgG opsonized virions induces aggregation. HIV incubated with human
(A) 1F7, (B) HIV-Ig, or (C) anti-HLA-DR antibody followed by removal of
free antibody, and addition of a secondary anti-Fc. Complex size is
measured in triplicate by DLS. Data shown represent the mean of three
experiments.
Additional file 2: Figure S2. HIV-1 (A) BaL and (B) RF binds specifically
to 2F5 and b12 after isotype switching. Binding between b12 and 2F5
antibodies of IgG, dimeric IgA and pentameric IgM isotypes to virions
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covalently attached to a sensor cassette. Purified HIV-1BaL virions were
allowed to bind for 3 minutes, followed by 10 minutes of dissociation.
Affinities were calculated according to a Langmuir binding model.
Measurements were made in triplicate and data shown is representative
from one experiment.
Additional file 3: Figure S3. Size-exclusion chromatography and
dynamic light scattering in tandem enable characterization of the viral
complexes formed with 2F5 IgG. Virus incubated with 2F5 IgG was
separated over a size exclusion column and followed by absorbance
measured by (A) infrared, (B) ultraviolet, and (C) DLS detection. (D) Size
was determined from the peak eluted from the SEC system. One peak
was detected with the IgG preparation, eluted at 23.5 minutes and
measuring 176 nm. Experiments were performed in triplicate. Results
shown are from one representative experiment.
Additional file 4: Figure S4. Size-exclusion chromatography and
dynamic light scattering in tandem enable characterization of viral
complexes formed with b12 IgG. Virus incubated with b12 IgG was
separated over a size exclusion column and followed by absorbance
measured by with (A) infrared, (B) ultraviolet and (C) DLS detection. (D)
Size was determined from the one peak eluted from the SEC system.
One peak was detected with the IgG preparation, eluted at 23 minutes
and measuring 176 nm. Experiments were performed in triplicate. Results
shown are from one representative experiment.
Additional file 5: Figure S5. Western blots for IgA of purified IgA from
8 patients in the RV144 trial. IgA is separated on an 8% Native-PAGE gel
and transferred to a PVDF membrane. Plot is probed with goat
anti-human-IgA. Monomeric and dimeric forms of IgA are seen in
both the pre and post-immunization samples.
Additional file 6: Figure S6. Size distribution of purified HIV-1A244 and
IgA preparations from 8 patients. Size distribution of purified virions and
IgA isolated from 8 patient sera was measured using dynamic light
scattering. (A) Three preparations of purified virions were measured by
DLS and had similar size distributions, with a Z-average diameter of
216.6 nm. (B) Pre-immunization serum from 8 patients had the same size
distribution, with particles ranging from 6 to 12 nm in diameter. Results
shown are the average of three experiments, each measured in triplicate.
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